^Stojanovic I, Cuzzocrea S, Mangano K, Mazzon E, Miljkovic D, Wang M, et al. (June 2007). "In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models". Clinical Immunology. 123 (3): 311–23.
doi:
10.1016/j.clim.2007.03.004.
PMID17449326.
^Lee JC, Menacherry S, Diehl MC, Giffear MD, White CJ, Juba R, et al. (March 2016). "Safety, bioavailability, and pharmacokinetics of VGX-1027-A novel oral anti-inflammatory drug in healthy human subjects". Clinical Pharmacology in Drug Development. 5 (2): 91–101.
doi:
10.1002/cpdd.193.
PMID27138022.
S2CID22577185.
^Xu M, Li F, Wang M, Zhang H, Xu L, Adcock IM, et al. (January 2019). "Protective effects of VGX-1027 in PM2.5-induced airway inflammation and bronchial hyperresponsiveness". European Journal of Pharmacology. 842: 373–383.
doi:
10.1016/j.ejphar.2018.11.010.
hdl:10044/1/66292.
PMID30419239.
S2CID53292202.
^Ahmad SF, Nadeem A, Ansari MA, Bakheet SA, Alasmari F, Alasmari AF, et al. (November 2019). "The potent immunomodulatory compound VGX-1027 regulates inflammatory mediators in CD4+ T cells, which are concomitant with the prevention of neuroimmune dysregulation in BTBR T+ Itpr3tf/J mice". Life Sciences. 237: 116930.
doi:
10.1016/j.lfs.2019.116930.
PMID31610190.
S2CID204702143.
^Stojanovic I, Cuzzocrea S, Mangano K, Mazzon E, Miljkovic D, Wang M, et al. (June 2007). "In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models". Clinical Immunology. 123 (3): 311–23.
doi:
10.1016/j.clim.2007.03.004.
PMID17449326.
^Lee JC, Menacherry S, Diehl MC, Giffear MD, White CJ, Juba R, et al. (March 2016). "Safety, bioavailability, and pharmacokinetics of VGX-1027-A novel oral anti-inflammatory drug in healthy human subjects". Clinical Pharmacology in Drug Development. 5 (2): 91–101.
doi:
10.1002/cpdd.193.
PMID27138022.
S2CID22577185.
^Xu M, Li F, Wang M, Zhang H, Xu L, Adcock IM, et al. (January 2019). "Protective effects of VGX-1027 in PM2.5-induced airway inflammation and bronchial hyperresponsiveness". European Journal of Pharmacology. 842: 373–383.
doi:
10.1016/j.ejphar.2018.11.010.
hdl:10044/1/66292.
PMID30419239.
S2CID53292202.
^Ahmad SF, Nadeem A, Ansari MA, Bakheet SA, Alasmari F, Alasmari AF, et al. (November 2019). "The potent immunomodulatory compound VGX-1027 regulates inflammatory mediators in CD4+ T cells, which are concomitant with the prevention of neuroimmune dysregulation in BTBR T+ Itpr3tf/J mice". Life Sciences. 237: 116930.
doi:
10.1016/j.lfs.2019.116930.
PMID31610190.
S2CID204702143.